Single cEll pRofiling PErsistaNce To ImmuNothErapy

The SERPENTINE trial (ESR 21-21165) is a phase II clinical study aiming to evaluate the efficacy of durvalumab and tremelimumab, alone or in combination, in patients with colorectal or endometrial cancer. The trial targets patients with microsatellite instability-high (MSI-H) tumors and those with microsatellite stable (MSS) tumors. Colorectal and endometrial cancers present significant challenges due to their heterogeneity and variable responses to treatment. Immunotherapy, particularly checkpoint inhibitors like durvalumab and tremelimumab, has shown promise in some patients, but predicting response remains elusive. The SERPENTINE trial aims to address this gap by investigating the effectiveness of these immunotherapies in a carefully selected patient population.

NCT Number	NCT06680739
Lead Sponsor	Vall d'Hebron Institute of Oncology
Conditions	Colorectal Cancer, Endometrial Cancer
Enrollment	60 participants
Start Date	2022-03-01
Primary Completion	2032-07-01 (estimated)
Study Completion	2032-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-01